Sathyen A Prabhu, Omar Moussa, Christophe Gonçalves, Judith H LaPierre, Hsiang Chou, Fan Huang, Vincent R Richard, Pault Y M Ferruzo, Elizabeth M Guettler, Isabel Soria-Bretones, Laura Kirby, Natascha Gagnon, Jie Su, Jennifer Silvester, Sai Sakktee Krisna, April A N Rose, Karen E Sheppard, David W Cescon, Frédérick A Mallette, Rene P Zahedi, Christoph H Borchers, Sonia V Del Rincon, Wilson H Miller
Aberrant cell-cycle progression is characteristic of melanoma, and CDK4/6 inhibitors, such as palbociclib, are currently being tested for efficacy in this disease. Despite the promising nature of CDK4/6 inhibitors, their use as single agents in melanoma has shown limited clinical benefit. Herein, we discovered that treatment of tumor cells with palbociclib induces the phosphorylation of the mRNA translation initiation factor eIF4E. When phosphorylated, eIF4E specifically engenders the translation of mRNAs that code for proteins involved in cell survival...
February 1, 2023: Molecular Cancer Therapeutics